| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Revenues: | ||||||
Research and development revenue | ||||||
1,681 | 1,295 | 758 | ||||
Costs and expenses: | ||||||
Costs of research and development revenue | ||||||
1,459 | 1,027 | 680 | ||||
Provision for contract losses | ||||||
- | - | 220 | ||||
Research and development | ||||||
3,087 | 2,101 | 1,765 | ||||
Research and development - related party | ||||||
900 | 1,200 | 437 | ||||
General and administrative | ||||||
5,519 | 4,522 | 5,030 | ||||
Foreign currency exchange loss (gain), net | ||||||
-27 | -20 | 249 | ||||
Total costs and expenses | ||||||
10,963 | 8,887 | 7,885 | ||||
Loss from operations | ||||||
-9,282 | -7,592 | -7,126 | ||||
Settlement of litigation, net | ||||||
- | - | 4,358 | ||||
Interest income | ||||||
984 | 894 | 566 | ||||
Total other income | ||||||
- | - | 4,924 | ||||
Loss before income taxes | ||||||
-8,297 | -6,697 | -2,202 | ||||
Provision for income taxes | ||||||
10 | -1,006 | -66 | ||||
Net loss | ||||||
-8,307 | -5,691 | -2,135 | ||||
Basic and diluted net loss per common share (USD per share) | ||||||
-0.31 | -0.21 | -0.07 | ||||
Basic and diluted weighted-average common shares outstanding (in shares) | ||||||
27,003 | 27,673 | 28,917 | ||||